ThomasBroderickMD

PubMed

• 81 citations
  Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
  Gregg W. Stone, Stephen G. Ellis, Tommaso Gori, D. Christopher Metzger, Bernardo Stein, Matthew Erickson, Jan Torzewski, Jerome Williams, William Lawson, Thomas M. Bro...> ;Lancet. 2018 Oct 27
• 1 citations
  CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
  Michael Essandoh, Adam A. Dalia, Barry George, Antolin S. Flores, Andrew J. Otey, Ajay J. Kirtane, Thomas M. Broderick, Sunil V. Rao> ;Journal of Cardiothoracic and Vascular Anesthesia. 2016 Dec 1
• 78 citations
  Thrombosis and drug-eluting stents: a critical appraisal.
  Dean J. Kereiakes, Joseph K. Choo, John J Young, Thomas M. Broderick> ;Reviews in Cardiovascular Medicine. 2004 Jan 1
• 81 citations
  Thrombosis and drug-eluting stents: a critical appraisal.
  Dean J. Kereiakes, Joseph K. Choo, John J Young, Thomas M. Broderick> ;Reviews in Cardiovascular Medicine. 2004 Jan 1
• 6 citations
  Quantification of Abciximab-Induced Platelet Inhibition Is Assay Dependent: A Comparative Study in Patients Undergoing Percutaneous Coronary Intervention
  Mark I. Furman, Dean J. Kereiakes, Lori A. Krueger, Michele N. Mueller, Thomas M. Broderick, John F. Schneider, Wendy L. Howard, Marsha L. Fox, Marc R. Barnard, Andrew...> ;American Heart Journal. 2003 Feb 1
• Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.
  John J Young, Daniel P. Marcus, Charles W. Abbottsmith, Thomas M. Broderick, Joseph K. Choo, John Paul Runyon, John F. Schneider, Thomas M. Shimshak, Rodney P. Geier, ...> ;The Journal of Invasive Cardiology. 2003 Jan 1
• 1 citations
  Intragraft verapamil: an ounce of prevention is worth a pound of cure.
  Dean J. Kereiakes, John J Young, Joseph K. Choo, Thomas M. Broderick> ;The Journal of Invasive Cardiology. 2002 Jun 1
• 2 citations
  Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings.
  Dean J. Kereiakes, Joseph K. Choo, John J Young, Thomas M. Broderick> ;The Journal of Invasive Cardiology. 2002 Mar 1
• 11 citations
  Successful long-term therapy following saphenous vein-covered stent deployment for atherosclerotic coronary aneurysm.
  Dean J. Kereiakes, Thomas M. Broderick, Wendy L. Howard, Linda C. Anderson, Mark Weber, Donald L. Mitts> ;Catheterization and Cardiovascular Interventions. 2002 Jan 1
• 39 citations
  Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or ...
  Mark I. Furman, Dean J. Kereiakes, Lori A. Krueger, Michele N. Mueller, Karen Pieper, Thomas M. Broderick, John F. Schneider, Wendy L. Howard, Marsha L. Fox, Marc R. B...> ;American Heart Journal. 2001 Nov 1
• 2 citations
  Extensive thrombus prior to elective percutaneous coronary intervention.
  David E. Kandzari, Victor S. Behar, Michael H. Sketch, Dean J. Kereiakes, Thomas M. Shimshak, Thomas M. Broderick, John J Young, John Paul Runyon, Robert D. Safian, Mo...> ;The Journal of Invasive Cardiology. 2001 Jul 1
• 111 citations
  Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
  Dean J. Kereiakes, Cindy L. Grines, Edward T.A. Fry, Paolo Esente, D. A. Hoppensteadt, Mark Midei, L Barr, William H. Matthai, M Todd, Thomas M. Broderick, R Rubinstei...> ;The Journal of Invasive Cardiology. 2001 Apr 1
• 63 citations
  Dalteparin in combination with abciximab during percutaneous coronary intervention
  Dean J. Kereiakes, Neal S. Kleiman, Edward T.A. Fry, Grace Mwawasi, Rose Lengerich, Kelly Maresh, Mary Lynn Burkert, Joseph W. Aquilina, Michael DeLoof, Thomas M. Brod...> ;American Heart Journal. 2001 Mar 1
• 86 citations
  Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management
  Eric J. Dippel, Dean J. Kereiakes, Daniel A. Tramuta, Thomas M. Broderick, Thomas M. Shimshak, Eli M. Roth, Charles R. Hattemer, John Paul Runyon, David D. Whang, John...> ;Catheterization and Cardiovascular Interventions. 2001 Mar 1
• 6 citations
  Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes.
  Dean J. Kereiakes, John J Young, Thomas M. Broderick, Thomas M. Shimshak, Charles W. Abbottsmith> ;The American Journal of Cardiology. 2000 Dec 28
• 22 citations
  Abciximab provides cost-effective survival advantage in high-volume interventional practice.
  Dean J. Kereiakes, Robert L. Obenchain, Beth L. Barber, Andrew L. Smith, Mark McDonald, Thomas M. Broderick, John Paul Runyon, Thomas M. Shimshak, John F. Schneider, C...> ;American Heart Journal. 2000 Oct 1
• 52 citations
  Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials)
  Dean J. Kereiakes, Thomas J. Linnemeier, Donald S. Baim, Richard E. Kuntz, Charley O’Shaughnessy, James B. Hermiller, Stan Fink, Alexandra J. Lansky, Naomi Nishimura, ...> ;The American Journal of Cardiology. 2000 Aug 1
• 33 citations
  IIb's are not IIb's.
  Dean J. Kereiakes, John Paul Runyon, Thomas M. Broderick, Thomas M. Shimshak> ;The American Journal of Cardiology. 2000 Apr 27
• 9 citations
  Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
  Dean J. Kereiakes, Mark McDonald, Thomas M. Broderick, Eli M. Roth, David D. Whang, Linda H. Martin, Wendy L. Howard, John F. Schneider, Thomas M. Shimshak, Charles W....> ;American Heart Journal. 2000 Feb 1
• 35 citations
  Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
  Dean J. Kereiakes, Edward T.A. Fry, William H. Matthai, Niederman A, L Barr, Bruce R. Brodie, James P. Zidar, Paul N. Casale, Christy G, David J. Moliterno, Lengerich ...> ;The Journal of Invasive Cardiology. 2000 Feb 1
• 8 citations
  High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagon...
  Dean J. Kereiakes, Thomas M. Broderick, Eli M. Roth, David D. Whang, Michele N. Mueller, Pam Lacock, Linda C. Anderson, Wendy L. Howard, Chris Blanck, John F. Schneide...> ;Journal of Thrombosis and Thrombolysis. 2000 Feb 1
• Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
  Dean J. Kereiakes, Thomas M. Broderick, Charles W. Abbottsmith, Thomas M. Shimshak> ;The Journal of Invasive Cardiology. 2000 Feb 1
• 3 citations
  Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
  Tramuta Da, Dean J. Kereiakes, Eric J. Dippel, Lengerich R, Thomas M. Broderick, Charles W. Abbottsmith, D.D. Whang, Eli M. Roth, John F. Schneider, Wendy L. Howard, T...> ;The Journal of Invasive Cardiology. 2000 Jan 1
• 30 citations
  Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment.
  Dean J. Kereiakes, Mark Midei, James B. Hermiller, Charles O'Shaughnessy, Richard Schlofmitz, Steven J. Yakubov, Stan Fink, Frank B. Hu, Naomi Nishimura, Marina Siever...> ;The American Journal of Cardiology. 1999 Dec 15
• 109 citations
  Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneo...
  Dean J. Kereiakes, Thomas M. Broderick, Eli M. Roth, David D. Whang, Thomas A. Shimshak, John Paul Runyon, Charles R. Hattemer, John F. Schneider, Pam Lacock, Michele ...> ;The American Journal of Cardiology. 1999 Aug 15
• Join now to see all